PainReform Ltd.
PRFX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.03 | -0.04 | -0.02 |
| FCF Yield | -829.05% | -198.05% | -146.94% | -50.60% |
| EV / EBITDA | 0.19 | 0.48 | -0.03 | 0.48 |
| Quality | ||||
| ROIC | -675.24% | -126.50% | -78.74% | -39.35% |
| Gross Margin | 0.00% | 0.00% | 82.56% | 0.00% |
| Cash Conversion Ratio | 0.87 | 0.71 | 0.73 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | – | – | – |
| Free Cash Flow Growth | -88.91% | -3.45% | 2.09% | -157.23% |
| Safety | ||||
| Net Debt / EBITDA | 0.29 | 0.83 | 0.47 | 2.30 |
| Interest Coverage | -1,048.07 | -24.96 | -145.39 | -720.80 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -6,752.50 | -5,377.67 | 185,507.43 | -7,091.43 |